This study is about two years long. It consists of following- Screening period (2 weeks) Double-blind study treatment period (48 weeks) Open-label extension (48 weeks) Safety followup period (8 weeks)

Who can Participate

At least 18 years old, Clinical diagnosis of primary Sjogren's disease. Secondary Sjogren's disease diagnosis is excluded. Inclusion- Women of childbearing potential should agree to use contraceptive measures consistent with local regulations. Exclusion: -Any autoimmune disease that would interfere with accurate assessment of clinical symptoms of pSjD. -Active, not adequately controlled fibromyalgia, or participant who is receiving fibromyalgia treatment that has not been stable for at least 12 weeks before screening. -Any severe systemic pSjD manifestation that is not adequately controlled at baseline that may put the participant at undue risk based on the investigator's opinion. -Severe renal impairment -Comorbidities for example, asthma, chronic obstructive pulmonary disease, which have required 3 or more courses of systemic glucocorticoids within previous 12 months

Study ID